EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial

Tian-Tian Yu iD, Xiao Hu, Wei-Jian Liufu, Shao-Qing Niu, Hui-Min Lian, Hong-Lian Ma, Jin Wang, Yong Bao, Ming Chen, Fang Peng

Cancer Medicine · 2024

DOI: 10.1002/cam4.7215 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Tian-Tian Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Etoposide, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The recommended treatment for limited‐stage small‐cell lung cancer (LS‐SCLC) is a combination of thoracic radiotherapy (TRT) and etoposide plus cisplatin (EP) chemotherapy, typically administered over 4–6 cycles. Nonetheless, the optimal duration of chemotherapy is still not determined. This study aimed to compare the outcomes of patients with LS‐SCLC who received either 6 cycles or 4–5 cycles of EP chemotherapy combined with TRT. Materials and Methods In this retrospective analysis, we utilized data from our prior prospective trial to analyze the outcomes of 265 LS‐SCLC patients who received 4–6 courses of EP combined with concurrent accelerated hyperfractionated TRT between 2002 and 2017. Patients were categorized into two groups depending on their number of chemotherapy cycles: 6 or 4–5 cycles. To assess overall survival (OS) and progression‐free survival (PFS), we employed the Kaplan–Meier method after conducting propensity score matching (PSM).

Results

Among the 265 LS‐SCLC patients, 60 (22.6%) received 6 cycles of EP chemotherapy, while 205 (77.4%) underwent 4–5 cycles. Following PSM (53 patients for each group), the patients in the 6 cycles group exhibited a significant improvement in OS and PFS in comparison to those in the 4–5 cycles group [median OS: 29.8 months (95% confidence interval [CI], 23.6–53.1 months) vs. 22.7 months (95% CI, 20.8–29.1 months), respectively, p = 0.019; median PFS: 17.9 months (95% CI, 13.7–30.5 months) vs. 12.0 months (95% CI, 9.8–14.2 months), respectively, p = 0.006]. The two‐year and five‐year OS rates were 60.38% and 29.87% in the 6 cycles group, whereas 47.17% and 15.72% in the 4–5 cycles group, respectively.

Conclusion

Patients diagnosed with LS‐SCLC who were treated with EP regimen chemotherapy combined with TRT exhibited notably enhanced survival when administered 6 cycles of chemotherapy, as compared to those who underwent only 4–5 cycles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaEtoposideLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPropensity ScoreCisplatinChemoradiotherapyHumansMaleFemaleMiddle AgedAgedRetrospective StudiesProspective StudiesNeoplasm StagingAdultProgression-Free SurvivalDrug Administration Schedule

Stichwörter der Autor:innen

chemotherapyconcurrent chemoradiotherapycycles of chemotherapylimited‐stage SCLCradiotherapy

Substanzen

EtoposideCisplatin

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center…
  • United Laboratory of Frontier Radiotherapy Technology of Sun Yat-Sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd, Guangzhou, China.

ORCID-Profile: Tian-Tian Yu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Yu, T. T., Hu, X., Liufu, W. J., Niu, S. Q., Lian, H. M., Ma, H. L., Wang, J., Bao, Y., Chen, M., & Peng, F. (2024). Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial. Cancer Medicine. https://doi.org/10.1002/cam4.7215

Vancouver

Yu TT, Hu X, Liufu WJ, Niu SQ, Lian HM, Ma HL, et al. Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial. Cancer Medicine. 2024. doi:10.1002/cam4.7215

BibTeX
@article{Yu2024,
  author = {Yu, Tian-Tian and Hu, Xiao and Liufu, Wei-Jian and Niu, Shao-Qing and Lian, Hui-Min and Ma, Hong-Lian and Wang, Jin and Bao, Yong and Chen, Ming and Peng, Fang},
  title = {Six versus four or five cycles of first‐line etoposide and platinum‐based chemotherapy combined with thoracic radiotherapy in patients with limited‐stage small‐cell lung cancer: A propensity score‐matched analysis of a prospective randomized trial},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7215}
}
Kostenlos starten →